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1. Introduction 
Robert Koch discovered the acid-fast bacterium that is the pathogenic germ of tuberculosis 
(TB) in 1882 [1]. TB is a major public health problem in the world and the leading cause of 
death from a single infectious agent. The World Health Organization estimates that one 
third of the world’s population is infected with Mycobacterium tuberculosis, and annually 
reports the global burden of the disease caused by TB. Over 8 million new cases and nearly 
1.5 million deaths from TB occur each year, presenting a significant threat to the world 
health [2]. The pathogenicity of mycobacteria is related to their ability to evade being 
ingested by macrophages, produce latent infection, and induce delayed-type 
hypersensitivity lesions such as granulomas. Moreover, the global spread of multi- and 
extensively drug-resistant TB (MDR-TB and XDR-TB, respectively) and the number of 
immunocompromised hosts, including victims of the human immunodeficiency virus (HIV) 
epidemic, are important problems [3]. 
The mycobacteria include the TB-causative acid-fast bacteria that are widely pathogenic to 
humans: M. tuberculosis, M. avium-intracellulare complex (MAC), M. leprae, and M. bovis, the 
source of the only available TB vaccine, Bacillus Calmette Guérin (BCG). The acid-fast 
bacteria are rich in lipids, and many mycoloyl glycolipids, such as cord factor/trehalose-6,6’-
dimycolate (TDM), phenolic glycolipid (PGL), sulfolipid (SL), glycopeptidolipid (GPL), 
phosphatidylinositol mannoside (PIM), lipomannan (LM), and lipoarabinomannan (LAM), 
are distributed in the cell wall [4-7]. Among them, glycolipids specific to the mycobacteria 
play a key role in the pathogenesis, because mycobacteria have large amounts of lipids that 
possess pleiotropic activities. The complex interaction between a range of mycobacterial 
components and the host cause the pathogenesis. 
In this review, the distribution of major glycolipids in several Mycobacteria and structural 
analyses using mass spectrometry (MS) are described. MS and MS/MS are useful to analyze 
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the glycosyl linkage, composition, and sequence of the sugar moiety. These results make it 
possible to discuss the heterogeneity and biosynthesis of glycolipids, and host responses to 
them. We hope that this review will promote better understanding of the structure-function 
relationships of glycolipids and open new avenues for prevention of infectious diseases. 
2. Distribution of glycolipids and phospholipids in mycobacteria 
The cell envelope surrounds the cytoplasm and is important for bacterial physiology and 
protection of microorganisms from their environment. Unlike other pathogenic microbes, 
the cell envelope of the acid-fast bacteria, including mycobacteria, is wax-like. The 
characteristic component is mycolic acids (MAs) which are α-branched β-hydroxy fatty 
acids (FAs), and have species-specific carbon-chain lengths and subclasses (α, methoxy, 
keto, dicarboxy, epoxy, etc.). The total lipid fraction was extracted with 
chloroform/methanol (3:1 and 2:1 v/v) and developed by two-dimensional thin-layer 
chromatography (TLC). Many glycolipids and phospholipids were detected, as shown in 
Fig. 1. Some glycolipids, such as cord factor/TDM and trehalose 6-monomycolate (TMM), 
exist ubiquitously in mycobacteria, and other glycolipids, including SLs and penta-acyl 
trehalose, exist only in virulent strains [8]. In general, the mycobacterial species have 
heterogeneous compositions and concentrations of glycolipids. According to current models 
of the mycobacterial cell envelope, which are ultimately based on an idea of Minnikin [9], 
arabinogalactan-attached MAs are believed to form one highly-arranged leaflet of a second 
membrane-like structure adjacent to the cell-wall skeleton (CWS). Complemented by other 
lipids forming the outer leaflet, this structure represents a very hydrophobic barrier that is 
responsible for the resistance to certain drugs [10]. The free glycoconjugates of MA, in 
particular TMM and cord factor/TDM, appear to be more difficult to localize, and 
occasionally they are described or depicted as distributed on the cell surface or buried more 
deeply in the cell envelope. A proposed structure of the mycobacterial cell envelope is 
shown in Fig. 2 [4, 11, 12]. 
 
Figure 1. TLC of total lipids derived from Mycobacterium tuberculosis Aoyama B strain. 
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Figure 2. Schematic representation of mycobacterial cell envelope. 
3. Host responses to mycobacterial glycolipids 
Mycobacteria are intracellular pathogens. Mycobacterial infection has dual consequences for 
the host: development of inflammatory lesions and clearance of the pathogen. Genetic 
regulation and expression of cell-mediated immunity and delayed-type hypersensitivity 
play critical roles in the outcome. Cell-mediated immunity participates in host defense, 
whereas delayed-type hypersensitivity is involved in the development of granulomatous 
inflammation. After invasion to the host cell, the mycobacteria multiply inside 
macrophages. The mechanism of pathogenesis is focused on evading the host’s killing 
system and induction of delayed-type hypersensitivity [13]. Certain cell wall glycolipids, 
such as cord factor/TDM, SL, and LAM [5-7], are involved in the host-pathogen interaction, 
and induce the primary host immune responses. 
Peptides and proteins with a wide range of antigenic moieties are recognized by the host 
immune system using major histocompatibility complex (MHC) class I or II. The recognition of 
lipids is important for host defense against mycobacterial infection as well as other antigenic 
responses. Several bacterial lipid antigens are recognized by specific T cells. MA derived from 
mycobacteria is a lipid antigen that stimulates CD1b-restricted T cells [14, 15].  Other 
immunogenic mycobacterial glycolipids, glucose-6-monomycolate (GMM), PIM, and LAM, 
are available for loading onto CD1 molecules and recognized by specific T cells [16, 17]. 
4. Mycoloyl glycolipids 
Acid-fast bacteria produce several mycolyl glycolipids that are composed of sugar and MA. 
The carbon-chain lengths and subclasses of MAs are species-specific. Nocardia, Rhodococcus, 
and Diezia species have short carbon-chain length MAs, and the subclass is mainly the α 
type. MAs of Mycobacterium species have long carbon-chains and are of various subclasses 
(α, methoxy, keto, dicarboxy, and epoxy types). In general, the average number of carbons 
in MAs increases from Dietzia, Rhodococcus, Nocardia, and Gordona to Mycobacteria. The MAs  
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are extracted with n-hexane or chloroform after alkaline-hydrolysis of heat-killed bacteria, 
and the subclasses are detected by using TLC developed with methyl ester derivatives (Fig. 
3). The molecular species of the MA subclasses are determined by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) using an Ultraflex 
II (Bruker Daltonics, Billerica, MA, USA) with 10 mg/ml 2,5-dihydroxybenzoic acid (DHB) in 
chloroform-methanol (1:1, v/v) as a matrix, and analyzed in Reflectron mode with an 
accelerating voltage operating in positive mode at 20 kV (Fig. 4). The MAs with short 
carbon-chains can be analyzed by using gas-chromatography mass spectrometry GC/MS. 
The trimethylsilyl derivatives of MA methyl esters are volatile, and the GC/MS spectra show 
specific fragment patterns that are assigned to detailed structures (Fig. 5), although the MAs 
with long carbon chains are difficult to vaporize and detect by GC/MS [18-20]. In addition, 
MAs are analyzed by using high performance liquid chromatography (HPLC) [21]. The 
resolution of HPLC is poor compared to that of GC/MS. GMM, fructose-6-monomycolate 
(FMM), and mannose-6-monomycolate (MMM) are produced by acid-fast bacteria cultured 
with their respective carbon source: glucose, fructose, and mannose. The structures are 
composed of MAs attached to glucose, fructose, and mannose, respectively, at the C6 
position [20, 22]. Recently, it was reported that M. tuberculosis produces GMM by 
transferring MA to glucose from cord factor/TDM, and thus evades the host immune system 
[23]. The molecular weights of mycoloyl glycolipids are measured by MALDI-TOF MS, and 
this information makes it possible to determine the combination of MA subclasses [24]. Cord 
factor/TDM is probably the most prominent and best-studied MA-containing compound of 
mycobacteria, and shows pleiotropic activities, including the development of 
granulomatous inflammation, anti-tumor immune response, and adjuvant effects based on 
the induction of proinflammatory and type 1 helper T cell (Th1)-related cytokines from host 
cells [25-27]. We demonstrated that administration of cord factor/TDM could induce 
delayed-type hypersensitivity-like lesions and foreign-body granulomas in euthymic and 
athymic mice, regardless of preimmunization with mycobacteria and cord factor/TDM. In 
fact, preimmunized mice challenged with cord factor/TDM developed more severe lesions 
than unimmunized mice. At the active lesion, CC-chemokines attracting monocytes, 
proinflammatory cytokines, and immunoregulatory cytokines were found. The 
inflammatory and cytokine responses were augmented in immunized mice challenged with 
cord factor/TDM. As a result, cord factor/TDM can induce both foreign body-type 
(nonimmune) and hypersensitivity-type (immune) granulomas by acting as a nonspecific 
irritant and T-cell-dependent antigen, and both nonimmune and immune mechanisms 
participate in granulomatous inflammation induced by mycobacterial infection [13, 28]. 
Moreover, rhodococcal cord factor/TDM induced milder granulomatous lesions than a 
mycobacterial one, implying that the proinflammatory responses induced by cord 
factor/TDM are in proportion to the carbon-chain length and subclasses of MAs in addition 
to carbon species [20, 29]. Recently, it was clarified that macrophage-inducible C-type lectin 
(mincle) is an essential receptor for cord factor/TDM [30]. Mincle is a receptor for sugar, and 
our previous result showed that the proinflammatory responses are MA-dependent. I expect 
the discovery of other unknown receptors for cord factor/TDM in addition to mincle. 
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Figure 3. TLC of mycolic acid methyl esters derived from Mycobacterium, Rhodococcus, and Dietzia species. 
 
Figure 4. MALDI-TOF MS spectra of mycolic acid methyl ester subclasses from M. tuberculosis H37Rv. 
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Figure 5. Total ion chromatogram and mass spectrum of mycolic acid trimethylsilyl derivatives from  
R. equi. 
5. Glycopeptidolipid (GPL) 
GPLs are produced by MAC, M. scrofulaceuem, M. chelonae, M. fortuitum, and M. smegmatis. 
Structurally, a GPL is composed of two parts, a common tetrapeptido-amino alcohol core 
and a serotype-specific oligosaccharide (OSE) elongated from 6-deoxy-talose (6-d-Tal). D-
phenylalanine-D-allo-threonine-D-alanine-L-alaninol (D-Phe-D-allo-Thr-D-Ala-L-alaninol), 
which is modified with an amido-linked 3-hydroxy or 3-methoxy C26-C34 FA at the N-
terminal of D-Phe; D-allo-Thr and terminal L-alaninol are further linked to a 6-d-Tal and 
3,4-di-O-methyl rhamnose (3,4-di-O-Me-Rha), respectively [31]. This portion is common to 
all serotypes, and is called the serotype-nonspecific GPL (apolar GPL), which exhibits 
antigenicity [11]. Serotype-specific GPLs (polar GPLs) are further glycosylated with a 
variable haptenic OSE at 6-d-Tal. We determined the structures of the serotype 7, 13, and 
16 GPLs and identified the gene clusters completing the OSE biosynthesis [32-34]. In 
addition, two methyltransferase genes of serotype 7- and 12-specific GPL biosynthesis 
were characterized [35]. The standard technique to classify MAC strains has employed 
serologic typing based on the OSE residue of the GPL. Recently, the biosynthetic pathway 
of various haptenic OSEs has been explored, and the genes encoding the pathways have 
been identified and characterized [36-38]. At present, 31 distinct serotype-specific polar 
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GPLs have been identified biochemically, and the complete structures of 17 GPLs are 
defined [12, 33]. The GPL present on the cell wall is considered to affect colony 
morphology. The MAC colony phenotype spontaneously changed from a smooth to a 
rough type, and this was due to a mutation lacking GPLs [39, 40]. The polar GPLs 
produced by MAC species are of particular interest because they are considered to be 
correlated with the physiology of the bacteria and the host responses to MAC infection, 
for example, colony morphology, sliding motility, biofilm formation, immune 
modulation, and virulence [40-43]. 
We have demonstrated the applicability of serodiagnosis of MAC pulmonary diseases 
using the GPL and GPL core antigens, and have also shown that the levels of GPL and 
GPL core antibodies reflect disease activity [44-46]. The GPLs are produced by MAC 
species but are absent in M. tuberculosis, making it possible to distinguish MAC from 
tuberculous mycobacteria [44, 47]. An anti-GPL antibody is produced in the sera of 
patients and the level reflects the extent of disease, which is useful in diagnosis and 
treatment [48, 49]. GPLs are one of the immunologically active molecules characteristic of 
MAC, and serotype-specific GPLs participate in the pathogenesis and 
immunomodulation in the host [50, 51]. It has been reported that the GPL core plays a 
role in suppression of mitogen-induced blastogenic response in spleen cells [52]. In 
addition, the immunomodulating activity of GPL on macrophage functions is serotype-
dependent [53]. The serotype 4 GPL promotes phagocytosis and inhibits phagosome-
lysosome (P-L) fusion, whereas the GPLs of serotypes 9 and 16 exhibit no effect on 
phagocytosis and P-L fusion. The serotype 8 GPL shows concomitant stimulation of both 
phagocytosis and P-L fusion. Because the GPL core, but not OSE, is common in all 
serotypes, the OSE of GPL may be involved in the mechanism of inhibition of P-L fusion, 
which is mediated through mannose receptors of macrophages [54]. The serotype 4 GPL 
inhibits the lymphoproliferative response to mitogens [51]. Thus, host responses to GPLs 
vary with the MAC serotype. It is reported that the uptake by and growth in 
macrophages of a MAC mutant with a gene in the GPL synthesis pathway inactivated by 
a transposon insertion were decreased [55]. The pathogenicity of GPL may comprise both 
a common peptide core and an OSE elongated from 6-d-Tal. The GPL is a pleiotropic 
molecule and participates in the pathogenesis of MAC disease. Elucidation of the 
structure-activity relationship of GPL is required for a better understanding of the 
pathogenesis. 
6. Structural analysis of GPL 
The polar GPL is species-specific in the portion of the OSE. MS is very useful to  
analyze the structure of OSE sequences and linkage positions in addition to total 
molecular weight. In this review, I describe detailed methods and results of structural 
analyses of some GPLs. The procedure for structural analysis of OSE is summarized in 
Fig. 6. 
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Figure 6. Procedure for structural analyses of OSE. 
6.1. Preparation of GPL 
MAC was grown on Middlebrook 7H11 agar (Difco Laboratories, Detroit, MI, USA) with 
0.5% glycerol and 10% Middlebrook OADC enrichment (Difco) at 37°C for 2-3 weeks. Heat-
killed bacteria were sonicated, and total lipids were extracted with chloroform-methanol 
(2:1, v/v). The total lipids were hydrolyzed with 0.2 N sodium hydroxide in methanol at 
37°C for 2 h, followed by neutralization with 6 N hydrochloric acid. Alkaline-stable lipids 
were partitioned by a two-layer system with chloroform-methanol (2:1, v/v) and water. The 
organic phase was evaporated and precipitated with acetone to remove any acetone-
insoluble components. The supernatant was partially purified with a Sep-Pak Silica 
Cartridge (Waters Corporation, Milford, MA, USA). The GPL was completely purified by 
preparative TLC of silicagel G (Uniplate; 20  20 cm, 250 µm; Analtech, Inc., Newark, DE, 
USA). The TLC plate was developed with chloroform-methanol-water (65:25:4 and 60:16:2, 
v/v), until a single spot was obtained. 
6.2. Preparation of OSE moiety 
-Elimination of the GPL was performed with alkaline borohydride, and the OSE 
elongated from D-allo-Thr was released [34, 56]. The GPL was stirred in a solution of 
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equal volumes of ethanol and 10 mg/ml sodium borodeuteride in 0.5 N sodium hydroxide 
at 60°C for 16 h. The reaction mixture was decationized with Dowex 50W X8 beads (Dow 
Chemical Company, Midland, MI, USA), and evaporated under nitrogen to remove boric 
acid. After partition into two layers of chloroform-methanol (2:1, v/v) and water, the 
upper aqueous phase was recovered and evaporated, and the OSE was purified as an 
oligoglycosyl alditol. 
6.3. Molecular weight of intact GPL 
The molecular species of the intact GPL was determined by MALDI-TOF MS. One µg of the 
GPL dissolved with chloroform-methanol (2:1,v/v) was applied to the target plate, and 1 µl 
of 10 mg/ml DHB in chloroform-methanol (1:1, v/v) was added as a matrix. The intact GPL 
was analyzed in the Reflectron mode with an accelerating voltage operating in positive 
mode at 20 kV [57]. The peak ions of intact GPL were detected in sodium adduct form, 
[M+Na]+ as the main molecular-related ion; representative spectra of some GPLs are shown 
in Fig. 7. The mass numbers identified the proposed structures of each GPL. 
 
 
 
 
 
 
Figure 7. MALDI-TOF MS spectra of representative GPLs. 
6.4. Glycosyl sequences of OSE. 
The molecular weight of the OSE portion is measured by MALDI-TOF MS. The OSE and 10 
mg/ml DHB were dissolved in ethanol-water (3:7, v/v) and applied to the target plate 
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according to the method for intact GPL. To determine the glycosyl sequence of the OSE, 
MALDI-TOF MS/MS analysis of the oligoglycosyl alditol from the OSE was performed. The 
spectrum afforded the molecular ion [M+Na]+, together with the characteristic mass 
increments in the series of glycosyloxonium ions formed on fragmentation at each glycosyl 
linkage from both terminal sugars to their opposites, respectively. It was shown the 
representative assignments of intact serotype 13 GPL and its OSE with the proposed 
structure in Fig. 8. 
 
Figure 8. MALDI-TOF MS and MS/MS spectra of serotype 13 GPL. The molecular weight of the intact 
GPL was detected as m/z 1897 for [M+Na]+ and fixed the proposed structure. The MS/MS spectra clearly 
show that the each ion was assigned to the fragmentation at each glycosyl linkage from both terminal 
sugars to their opposites, respectively. 
6.5. GC/MS of carbohydrates 
To determine the glycosyl composition and linkage position, GC/MS of partially methylated 
alditol acetate derivatives was performed. Perdeuteromethylation was conducted by the 
modified procedure of Hakomori [34, 58]. The OSE was dissolved with a mixture of 
dimethylsulfoxide and sodium hydroxide, followed by the addition of deuteromethyl iodide. 
After stirring at room temperature for 15 min, the reaction mixture was separated by a two-
layer system of water and chloroform. The chloroform-containing perdeuteromethylated OSE 
layer was collected, washed twice with water, and evaporated completely. Partially 
deuteromethylated alditol acetate derivatives were prepared from perdeuteromethylated OSE 
by hydrolysis with 2 N trifluoroacetic acid at 120°C for 2 h, reduction with 10 mg/ml sodium 
borodeuteride at 25°C for 2 h, and acetylation with acetic anhydride at 100°C for 1 h [34, 59]. 
GC/MS was performed using a fused capillary column (SP-2380 and Equity-1; 30 m, 0.25 mm 
ID, Supelco, Bellefonte, PA). The linkage positions were acetylated, and no related positions 
were previously deuteromethylated. The linkage positions were assigned by the 
fragmentation patterns of partially deuteromethylated alditol acetate derivatives and retention 
time of the peaks. The representative fragmentation patterns of partially methylated alditol 
acetate derivatives are shown in Fig. 9. 
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Figure 9. Representative mass spectrum of partially deuteromethylated alditol acetate derivatives. 
6.6. Nuclear magnetic resonance (NMR) of GPL 
The OSE was dissolved in deuterium oxide. To define the anomeric configurations of each 
glycosyl residue, 1H and 13C nuclear magnetic resonance (NMR) was employed. Both 
homonuclear correlation spectrometry (COSY) and 1H-detected [1H, 13C] heteronuclear 
multiple-quantum correlation (HMQC) were performed as described previously [34, 56]. 
The 1H NMR and 1H-1H homonuclear COSY analyses of the OSE derived from the GPL 
revealed distinct anomeric protons with corresponding H1-H2 cross-peaks in the low-field 
region, and the chemical shift and coupling constant are indicative of -anomers and a -
hexosyl unit, respectively. 
 
Glycosylation 112 
7. Biosynthesis gene of GPL 
7.1. Isolation of cosmid clones carrying rtfA gene and sequence analysis 
First, we constructed the M. intracellulare cosmid library. Genomic DNA of MAC was 
prepared by mechanical disruption of bacterial cells, which was accomplished by 
homogenizing a bacterial pellet with glass beads in phosphate-buffered saline, followed by 
phenol-chloroform extraction, and precipitation with ethanol. Genomic DNA fragments 
randomly sheared to 30–50 kb fragments during the extraction process were fractionated 
and electroeluted from agarose gels using Takara Recochip (Takara, Kyoto, Japan). These 
DNA fragments were rendered blunt-ended using T4 DNA polymerase and dNTPs, 
followed by ligation to dephosphorylated arms of pYUB412 (XbaI-EcoRV and EcoRV-XbaI). 
After in vitro packaging using Gigapack III Gold extracts (Stratagene, La Jolla, CA, USA), 
recombinant cosmids were introduced into the E. coli STBL2 [F–mcrA D (mcrBC-hsdRMS-
mrr) endA1 recA1 lon gyrA96 thi supE44 relA1 l- D (lac-proAB)]. PCR was used to isolate 
cosmid clones carrying the rhamnosyltransferase (rtfA) gene with primers rtfA-F (5’-
TTTTGGAGCGACGAGTTCATC-3’) and rtfA-R (5’-GTGTAGTTGACCACGCCGAC-3’). 
RtfA encodes an enzyme responsible for the transfer of Rha to 6-d-Tal in the OSE [38, 60]. 
We isolated the cosmid clones #49 (accession no. AB274811) and #253 (accession no. 
AB355138), which are responsible for the biosynthesis of GPL 7 and 16, respectively. The 
insert of a cosmid clone was sequenced using a BigDye Terminator v3.1 Cycle Sequencing 
Kit (Applied Biosystems, Foster City, CA, USA) and an ABI Prism 310 gene analyzer 
(Applied Biosystems). The putative function of each open reading frame (orf) was identified 
by similarity searches between the deduced amino acid sequences and known proteins 
using BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) and FramePlot (http://www.nih.go. 
jp/~jun/cgi-bin/frameplot.pl), and the DNASIS computer program (Hitachi Software 
Engineering, Yokohama, Japan). The similarity of protein sequences of each ORF was 
compared to those of serotype 2, 4, 7, and 16 GPLs, and the genetic maps for GPL 
biosynthetic cluster are summarized in Fig. 10 [32, 36, 61]. The OSE of serotype 1 GPL 
produced by M. avium serotype 1 strain is composed of -L-Rha-(12)-6-d-L-Tal, which is 
the core OSE of all serotypes [12]. M. avium serotype 1 strain (NF113) was transformed with 
pYUB412-cosmid clone #253 containing the serotype 16-specific gene cluster. The 
transformant produced a serotype 16 GPL with a different Rf value on TLC compared to 
serotype 1 GPL. The molecular weights of intact GPLs and the fragment patterns of their 
OSEs were completely equivalent to the serotype 16 GPL. Next, we identified some orf 
functions of #253. We hypothesized that orf1, 16, and 17 in #253 were correlated with the 
glycosyltransferase by the similarity of ORF sequences, in addition to rtfA. They were 
compared to the productive GPLs of serotype 1 transformants inserted with the combination 
of orf1, 16, and 17. We determined that orf1, 17, and 16 were responsible for the elongation 
from 6-d-Tal-Rha to 6-d-Tal-Rha-Rha-Rha-Rha, and that these glycosyltransferases operated 
in this order, as shown in Fig. 11. After the elongation of an OSE, the OSE may be modified 
by aminotransferase, methyltransferase, and acyltransferase, and serotype 16 GPL may be 
completed. 
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Figure 10. Comparison and overview of genetic maps of GPL biosynthetic cluster.  (A), M. avium strain 
724 (serotype 2, accession no. AF125999); (B), M. avium strain A5 (serotype 4, accession no. AY130970); 
(C), M. intracellulare ATCC 35847 (serotype 7, accession no. AB274811); (D), M. intracellulare ATCC 
13950T (serotype 16, accession no. AB355138). 
 
 
 
Figure 11. Proposed elongation of OSE in serotype 16 GPL. 
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7.2. Native conformation of GPL and host response 
The native GPL was purified without alkaline treatment. The native GPLs were detected on 
TLC as several spots that expanded broadly and had different Rf values from that of the 
alkaline-treated GPL (Fig. 12). Alkaline treatment converged these spots into one spot. It 
was reported that the native GPLs were modified by several O-acetylations in the OSE 
portion and the alkaline treatment removed the acetylated groups [23, 33]. We are now 
analyzing in detail the positions and numbers of O‐acetylations in the OSE by using 
MALDI-TOF MS/MS. 
 
Figure 12. TLC of some native GPL fractions (non-alkali-treated). 
The importance of Toll-like receptor (TLR)-mediated responses has been studied in 
tuberculous infections. Means et al. reported that M. tuberculosis activated both TLR2 and 
TLR4, whereas heat-killed M. tuberculosis and MAC activated only TLR2 [62]. It was 
observed that MyD88- and TLR2-deficient mice have increased susceptibility to MAC 
infection compared to TLR4-deficient and wild-type mice [63]. These lines of evidence 
suggest that TLRs are related to host recognition of the MAC components containing GPLs 
and affect MAC infections. To clarify the host recognitions of GPLs via TLRs, we stimulated 
HEK-blue-2, and -4 cells (InvivoGen, San Diego, CA, USA) with native and alkaline-treated 
GPLs. HEK-blue-2 and -4 cells are HEK293 cells stably transfected with multiple genes for 
recognition of TLR2 and TLR4 (including the co-receptors MD2 and CD14). The native GPL 
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significantly activated HEK-blue-2 cells in a dose-dependent manner, but HEK-blue-4 cells 
did not respond (Fig. 13). The alkaline-treated GPL without O-acetylation did not activate 
either HEK-blue-2 or -4 cells. Re-acetylated alkaline-treated GPLs with O-acetyl groups 
substituted for all hydroxy groups of the OSE activated HEK-blue-2 cells, although the level 
of activation was lower than that of the native form. Moreover, we confirmed that only the 
native GPL stimulated mouse bone marrow-derived macrophages via TLR2 by using 
C57BL/6 and TLR2 knockout mice. Brennan and Goren first proposed that de-acetylated 
GPLs as alkaline-stable lipids, made it possible to classify serotyping [12, 31]. Schorey and 
colleagues clarified that serotype 1 and 2 GPLs can function as TLR2 agonists and promote 
macrophage activation in a TLR2 and MyD88-dependent pathway [64, 65]. They reported 
that the acetylated and methylated groups of GPLs were necessary for GPL-TLR2 
interaction as a molecular requirement. Taken together with our results, native GPLs are a 
TLR2 agonist, and it may be important for GPL-TLR2 interaction to balance the 
hydrophobicity and hydrophilicity of the GPL molecules. 
 
Figure 13. Native GPLs activate cells through TLR2. 
8. Sulfolipid (SL) 
Mycobacterial SLs are classified into three types by the number of attached short  
acyl chains. SL-1 is the predominant type, and SL-2 and -3 are intermediate types.  
The structure of SL-1 was identified as 2-palmitoyl(stearoyl)-3-phthioceranoyl-6,6’-bis-
hydroxyphthioceranoyl-trehalose-2’-sulfate [66, 67]. The presence of SLs in mycobacteria is 
strain-specific. Several studies have demonstrated a significant relationship between SL-1 
 
Glycosylation 116 
and virulence, such as the amount of SL-1 biosynthesis in virulent strains, and the inhibition 
of P-L fusion in macrophages by SL-1. SL-1 modulates superoxide release and secretion of 
interleukin (IL)-1 and tumor necrosis factor (TNF)- by blocking activation of human 
macrophages and neutrophils [68, 69]. In contrast to these studies, it has been reported that 
pks2 disruption and SL-1 deficiency do not significantly affect the replication, persistence, 
and pathogenicity of M. tuberculosis in mice, guinea pigs, or cultured macrophages [70, 71]. 
The pathogenicity of SL-1 is controversial. SL-1 does not induce granulomatous 
inflammation, but rather inhibits it and the release of TNF- induced by cord factor/TDM 
[72]. SL-1 could contribute to virulence at an early stage of mycobacterial infection by 
counteracting the immunopotentiating effect of cord factor/TDM. On the other hand, it is 
reported that SL-3, 2-palmitoyl(stearoyl)-3-hydroxyphthioceranoyl-trehalose-2’-sulfate, is 
mainly recognized by CD1b-restricted T cells as a lipid antigen. The other tetraacylated and 
triacylated SLs (SL-1 and -2) were unable to stimulate diacylated SL (SL-3)-specific T cell 
clones, which implies that immunogenic SL-3 are not generated inside the antigen-presented 
cells [73] 
SLs of M. tuberculosis have been implicated in the virulence of this organism by inhibiting 
the P-L fusion in macrophages, thus probably promoting the intracellular survival of M. 
tuberculosis, but the pathogenic role remains controversial. The gene, pks2, responsible for SL 
synthesis was identified and disrupted [74]. The pks2 mutant defective in an early step of SL 
biosynthesis had no obvious growth defect in infected mice. By contrast, growth of a strain 
lacking MmpL8, a transporter of SL in M. tuberculosis, was highly attenuated in a mouse 
model of tuberculosis [70]. Although initial replication rates and containment levels of the 
MmpL8 mutant were identical, compared with the wild type, a significant attenuation of the 
mutant strain in time-to-death was observed. Early in infection, differential expression of 
cytokines and cytokine receptors revealed that the mutant strain less efficiently suppresses 
key indicators of a Th1-type immune response, suggesting an immunomodulatory role for 
SLs in the pathogenesis of tuberculosis [75]. 
Recently, Kummer et al. demonstrate that PapA2 and PapA1 are responsible for the 
sequential acylation of SL1 biosynthesis. Disruption of papA2 and papA1 in M. tuberculosis 
confirmed their essential role in SL-1 biosynthesis and their order of action. BALB/c mice 
infected by aerosol with wild-type, ∆papA2, and ∆papA1 mutants showed no significant 
difference in the ability of the bacteria to grow or persist through the time to death of the 
mice. The loss of SL-1 did not appear to affect bacterial replication or trafficking. They 
suggested that the functions of SL-1 are specific to human infection [76]. 
9. Phenolic glycolipid (PGL) 
The glycosylated phenolphthiocerol dimycocerosates (PDIM), so-called PGLs, are produced 
by a limited group of mycobacterial species, and most of them are pathogenic in humans 
[77]. PGL is distributed in M. leprae as a unique antigen, and inhibits the 
lymphoproliferative responses and suppresses monocyte oxidative responses [78-80]. It has 
also shown that disruption of PGL synthesis results in loss of the virulent phenotype 
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without significantly affecting the bacterial load during disease in experimental models 
using mice and rabbits, and loss of PGL was found to correlate with an increase in the 
release of the pro-inflammatory cytokines in vitro [81, 82]. A PGL purified from M. leprae has 
been used as antigen in an enzyme-linked immunosorbent assay. Antibodies directed 
against the lipid were detected in sera of leprosy patients but not in sera from uninfected 
controls or patients infected with other mycobacteria, including M. tuberculosis. The 
antibody response distinguished between the M. leprae lipid and the structurally related 
PGL from M. kansasii. Similar to serodiagnosis of MAC disease using GPL, this assay based 
on PGL antigen has considerable potential as a specific serodiagnostic test for infection with 
M. leprae [83, 84]. 
We determined the structure of the PGL derived from BCG (Tokyo 172 strain). The PGL 
produced by BCG is a so-called mycoside B (PGL-BCG), and its sugar moiety is different 
from that of the PGL produced by M. tuberculosis (PGL-tb). The PGL-BCG has only a 2-O-
Me-Rha branch elongated from the phenol moiety, although PGL-tb has it elongated to three 
sugar residues [85]. The composition of the PDIM in PGL is similar in both species. The 
MALDI-TOF MS spectrum of PGL-BCG showed m/z 1531 and other mass units at 14 Da 
intervals for [M+Na]+ as molecule-related ions in positive mode (Fig. 14). In addition, the 
MS/MS spectrum showed fragment ion peaks m/z 1371 based on the elimination of methyl-
deoxysugar; m/z 1135, 1093, based on the elimination of the C26:0, C29:0 FAs; m/z 696 based 
on the elimination of both C26:0 and C29:0 FAs; and m/z 535 for the phenol phthiocerol that 
eliminated methyl-deoxysugar and C26:0, C29:0 FAs (Fig. 14). 
Reed et al. demonstrated that PGL-tb inhibits the innate immune response. Loss of PGL-tb 
was responsible for an increase in the release of TNF-α and IL-6 and IL-12 in vitro, and the 
PGL-tb-deficient mutant showed a phenotype with low virulence/pathogenicity [81]. The 
composition of the PDIM in PGL-BCG is similar to that in PGL-tb. Although purified PGL 
molecules by themselves had no effect on the activation of macrophages in vitro, we found 
that PGL suppressed the activation of murine bone marrow-derived macrophages elicited 
by total lipids. It is considered that the PGL may have a competitive inhibitory effect or 
mask the active site of other TLR2 agonistic lipid components, and decrease their activity. 
10. Phosphatidylinositol mannoside (PIM), lipomannan (LM), and 
lipoarabinomannan (LAM) 
PIMs and their multiglycosylated counterparts, LMs, and LAMs, are complex lipoglycans 
that are found ubiquitously in the envelopes of all mycobacterial species. Their structures 
originate from a phosphatidyl-myo-inositol (MPI) anchor, which is mannosylated to 
generate LM and further arabinosylated to give LAM [86]. The non-reducing termini of the 
arabinosyl side chains can be substituted by capping motifs, and LAMs are classified into 
three families. LAMs from slow growing mycobacteria bearing mannose caps, i.e. mono- or 
(12)-di- or trimannoside units, are designated as ManLAMs. In contrast, LAMs from fast 
growing mycobacteria capped by phospho-myo-inositol units and not capped at all, are 
termed PILAM and AraLAM, respectively [87]. LAMs and LMs exhibit a broad spectrum of  
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Figure 14. MALDI-TOF MS and MS/MS spectra of PGL derived from BCG Tokyo 172 strain, and 
proposed structure. 
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immunomodulatory activities, including the ability to modulate the production of 
macrophage-derived Th1 pro-inflammatory cytokines, most commonly TNF- and IL-12. 
The ManLAM from M. tuberculosis is involved in the inhibition of phagosome maturation, 
apoptosis, and IFN- signaling in macrophages and IL-12 secretion of dendritic cells. 
ManLAMs contribute an immunosuppressive effect to the persistence of slow-growing 
mycobacteria in humans. In contrast, PILAMs are able to induce the release of a variety of 
proinflammatory cytokines. Recently it was reported that LMs from both pathogenic and 
nonpathogenic mycobacterial species, independent of their origin, are potent stimulators of 
TNF-, IL-8, and IL-12, and activate macrophages via TLR2 [88-90]. The ManLAM/LM 
balance might be important to host immune responses against mycobacteria. 
PIMs are composed of a phsophatidylinositol and mannose moieties. PIMs have 4–6 
mannoses, the third and fourth of which are acylated in some cases. PIM2 containing two 
mannoses, a main component of mycobacterial cell walls, is highly immunogenic. Several 
biological functions have been recently attributed to PIMs. PIM2 was shown to recruit 
natural killer T cells, which play a role in the local granulomatous response [91, 92]. PIMs 
activate cells via TLR-2 [93]. PIM6 as well as the ManLAMs from M. leprae and M. 
tuberculosis are presented by antigen-presenting cells in the context of CD1b [17]. The 
phosphatidylinositol moiety plays a central role in the process of binding PIMs and 
ManLAMs to CD1b proteins. 
11. Conclusion 
Mycobacterial glycolipids are pleiotropic molecules and play key roles in both microbes and 
hosts by acting as structural components of cell walls and immunologically active 
substances. A better understanding of mycobacterial glycolipids will help us develop novel 
diagnostics, therapeutics, and prophylactics for mycobacterial diseases. 
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